- 503Pharma
- Posts
- 503Pharma Weekly Compounding Pharmacy Roundup
503Pharma Weekly Compounding Pharmacy Roundup
Your trusted source for compounding pharmacy education, news and insights.
503Pharma .
March 20, 2026
Now Hiring: Pharmacist-in-Charge — 503A Sterile Compounding Pharmacy (DFW, TX)
A pre-launch 503A sterile compounding pharmacy in Dallas-Fort Worth is looking for a licensed PIC to lead compliance and operations from day one. Sterile compounding experience required. Peptide/hormone background a plus.
Compensation: Competitive salary + full benefits (health, dental, vision, 401k) + equity participation in a ground-floor opportunity.
Interested? Send your CV to [email protected]
This Week's Headlines
From 503Pharma Blog
Labeling Compliance Checklist for Compounding Pharmacies
Labeling failures are one of the most common FDA inspection findings — and one of the most preventable. This checklist covers what 503A and 503B pharmacies are each required to include on every label, where most facilities fall short, and what documentation needs to be in place before a product leaves your facility.
Key areas covered:
503A — patient-specific prescription requirements, BUD assignments per USP 795/797, anticipatory compounding limits, and the "significant difference" prescriber notation
503B — required statements ("This is a compounded drug", "Not for resale", "For Office Use Only"), batch and lot tracking, facility identification, and MedWatch adverse event reporting info
Verification and cross-check procedures against master batch records (21 CFR § 211.125)
Common deficiencies FDA inspectors target: missing clinical difference documentation, incorrect BUDs, and inadequate patient identification on 503A prescriptions
Research
APC Publishes 2025–2026 Snapshot of Pharmacy Compounding
APC released its latest industry snapshot, surveying 600+ compounding professionals.
Key numbers:
Median 503A pharmacy dispenses 350 compounded Rxs per week, works with 150 prescribers, and prepares 100 unique formulations.
Pharmacists in the sector average 19 years of experience.
HRT remains the top category at 36% of dispensed therapies.
Over half of respondents compounded copies of FDA-approved drugs during active shortages.
Full report: a4pc.org
Policy Update
RFK Peptide Delisting — Still No Formal FDA Action
As covered last week, HHS Secretary Kennedy announced plans to move 14 peptides off the Category 2 "do not compound" list. As of March 19, no Federal Register notice has been issued and no FDA rule has changed.
Lead Story
GLP-1 Recalls: What Compounders Need to Know This Week
March 11 brought a cluster of GLP-1 quality failures that should put every compounding pharmacy on high alert. A finished-product sterility recall and two semaglutide API recalls for CGMP violations — signaling that FDA's enforcement focus has shifted from marketing claims to manufacturing quality.
New Life Pharma LLC (Northvale, NJ), using product manufactured by Nomida (Olathe, KS), recalled Tirzepatide Injection 15mg (Lot 240709, 45 vials) for "Lack of Assurance of Sterility." Small lot, but the sterility failure in a finished injectable is the signal — not the volume.
Simultaneously, two semaglutide API recalls were issued against Harbin Jixianglong Biotech (Harbin, China) for failing to complete process validation and bacterial endotoxin method validation before distribution — D-0380-2026 (Batch CP-030-20250911) and D-0379-2026. These are fundamental cGMP failures that should have halted distribution.
Action Items
If you received tirzepatide 15mg from New Life Pharma / Nomida, quarantine Lot 240709 immediately and notify affected patients
Request full validation packages from all API suppliers: process validation protocols, endotoxin testing certificates, sterility documentation — a COA alone is no longer sufficient
Review your own environmental monitoring logs and media fill records if you compound sterile GLP-1s
New from 503Pharma
90+ Compounding Formulas, Now Live in the Members Area
The 503Pharma Formula Library just launched at app.503pharma.com. Ready-to-use formulations for sterile and non-sterile compounding, built to current USP 795/797 standards, with BUD assignments included. Updated as guidance changes.
90+ formulations across sterile and non-sterile categories
BUD assignments aligned to USP 795 and 797
Ready to drop into your compounding records
Regularly updated as FDA and USP guidance evolves
The members area is free to join. Formula access is a paid feature.
CompoundLearn: Training Built for Compounding Pharmacies
CompoundLearn simplifies USP compliance training so your team can stay inspection-ready without the spreadsheets and paper trails. From onboarding new staff to competency testing, CompoundLearn automates the entire training lifecycle — so you can focus on what matters most: patient safety.
Full access to 25 training modules and 77 lessons covering critical USP 795, 797, and 800 topics
Role-based assignments — assign and track the right training curriculum to designated persons/pharmacists-in-charge, compounders, and trainers
Quizzes and Downloadable certificates that prove that your team knows the material
23+ Ready-Made Compliance Templates — Downloadable cleaning logs, sampling records, labeling checklists, and more — ready to use out of the box
Custom Module Creation — Build pharmacy-specific training for your unique protocols and SOPs
Team & Role Management — Assign training by role (designated person, compounder, technician) and track progress across your entire organization
✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.